Vanda Pharmaceuticals' Q4 Loss Widens on Higher Expenses

Vanda Pharmaceuticals reduced R&D expenses by 41%, but a tripling in SG&A expenses combined with modest Fanapt growth caused its loss to widen by 20%.

Feb 13, 2014 at 11:59AM

Vanda Pharmaceuticals (NASDAQ:VNDA), a biopharmaceutical company focused on developing therapies to treat central nervous system disorders, reported modest product growth and a wider net loss before the opening bell today.

In its fourth-quarter report, Vanda noted receiving $8.78 million in revenue, an expansion of 10.9% over the previous year as its net loss widened by 19.7% to $7.62 million. Adjusted EPS losses, however, matched the $0.23 loss reported in the year-ago period due to there now being 5 million more outstanding shares relative to the fourth quarter 2012.

Revenue for the quarter consisted of $6.75 million in amortized licensing revenue related to the $200 million upfront payment received from Novartis (NYSE:NVS) when it purchased the U.S. and Canadian rights to Vanda's FDA-approved schizophrenia drug, Fanapt in October 2009. Since this payment is amortized, it was consistent with the year-ago period. Royalty revenue from the sale of Fanapt, however, rose to $2 million from $1.2 million in the prior year. Furthermore, IMS reports indicate that 43,400 prescriptions for Fanapt were written during the fourth quarter, a 1% sequential decline from the third quarter, but a 14% year-over-year increase.

Total operating expenses for the quarter widened to $16.45 million from $14.35 million as a tripling in selling, general, and administrative expenses to $9.9 million more than offset a 41% decline in research and development expenses. These higher costs were the primary culprit of Vanda's wider net loss.

Although Vanda provided no specific financial guidance, it did note that it anticipates launching Hetlioz, the company's recently approved non-24-hour disorder drug to mediate sleep habits for the blind, sometime in the second quarter. It also ended the year with $130.4 million in cash, an improvement of $10 million over this time last year.

Vanda shares have been quite volatile following the announcement, falling as much as 10% shortly after it opened for trading and rising up to 12% thereafter. 


Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

The Motley Fool has no position in any companies mentioned in this article. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information